Product Description
Novel TACE/MMP inhibitor for rheumatoid arthritis
Mechanisms of Action: TNF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2004-002215-80 | P2 |
Completed |
Arthritis, Rheumatoid |
2013-01-01 |
|
2004-000012-13 | P2 |
Completed |
Arthritis, Rheumatoid |
2005-08-31 |
|
3140A1-200 | P2 |
Completed |
Arthritis, Rheumatoid |
2005-08-01 |